Vestibular Schwannoma Clinical Trial
Official title:
Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study
Title: Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a prospective randomized study Background: In patients undergoing microsurgical resection of a vestibular schwannoma, the facial and vestibulocochlear nerves are at risk. Prior studies suggested positive effects of nimodipine for preservation of the nerve function in these patients. A prospective, randomized, placebo controlled double-blinded study will be conducted to evaluate the neuro-protective effect of locally administered nimodipine during resection of vestibular schwannomas. Investigational drug: active group: "Nimotop® 10mg - Infusionsflasche" placebo: "Natrium chloratum physiologicum 0,9% - Medica Infusionslösung" Rationale for the study: Nimodipine is supposed to counteract the vasoconstriction of cerebral arteries caused by microsurgical manipulation and might thereby preserve facial and cochlear nerve function Aims of the study: Evaluation of the effect of intraoperative local administration of nimodipine on the postoperative function of the facial and vestibulocochlear nerves after microsurgical resection of vestibular schwannomas Study design: prospective, double-blinded, single-center, randomized phase III trial Study population: Patients undergoing microsurgical resection of a vestibularis schwannoma with a maximum diameter of 10-25mm on MRI at the Department of Neurosurgery, Medical university of Vienna. Number of Patients: 30 Methods: In 15 patients, nimodipine will be administered locally to the facial and vestibulocochlear nerves during resection of a vestibular schwannoma (= treatment group). In another 15 patients, a placebo (sodium chloride solution) will be administered. In both cases, a soaked gel foam pad will be used. The operating team and the patient will both be blinded during the procedure. Facial nerve function and hearing will be assessed prior and three months after surgery. Outcome variables: Serviceable or non-serviceable hearing according to Gardner-Robertson hearing scale and House-Brackmann score for the assessment of facial nerve function Statistical analysis: For the evaluation of the postoperative function of the vestibulocochlear nerve, the number of patients with postoperative serviceable hearing (Gardner-Robertson I-II) and postoperative non-serviceable hearing (Gardner-Robertson III-V) will be compared between both groups. For the evaluation of the facial nerve function, the number of patients with favorable postoperative outcome (House-Brackmann I-III) and non-favorable postoperative outcome (House-Brackmann IV-VI) will be compared. In both cases, fisher's exact test will be used. Expected risks/inconveniences: Administration of nimodipine is associated with the following adverse effects: thrombocytopenia, allergic reactions, headache, tachycardia, hypotension, nausea (occasionally) and bradycardia, ileus, reversibly elevated liver enzymes (seldom) Risk/benefit assessment: Expected adverse effects of local nimodipine administration are manageable and patients may profit from the use of nimodipine. No severe adverse events are expected.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | April 9, 2024 |
Est. primary completion date | April 9, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: - Age > 18a - Vestibular schwannoma with maximum diameter of 10-25mm on MRI - Pre-operative audiogram - Informed consent Exclusion Criteria: - Contraindication for nimodipine application - Vestibularis schwannoma diameter <10mm or >25mm on MRI |
Country | Name | City | State |
---|---|---|---|
Austria | Medical University of Vienna | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Facial nerve function | Function of the facial nerve according to House-Brackmann score. The House Brackmann score includes values from 1 to 6: 1 = normal function, 2 = minimal paresis, 3 = noticable paresis, 4 = severe paresis, 5 = minimum fuction, 6 = complete paralysis | 90 days after surgery | |
Primary | Hearing | Serviceable or non-serviceable hearing according to Gardner-Robertson scale. The Gardner-Robertson scale indludes values from 1 to 5: 1 and 2 indicating serviceable hearing, 3-5 indicating non-serviceable hearing. The scores from 1 to 5 differ in values of pure tone audiometry and speech discrimination, 1 indicates best function and 5 worst function. | 90 days after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Completed |
NCT04351373 -
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
|
Phase 2 | |
Active, not recruiting |
NCT01449604 -
Stereotactic Radiation in Vestibular Schwannoma
|
Phase 3 | |
Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
Not yet recruiting |
NCT05567341 -
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
|
N/A | |
Completed |
NCT02249572 -
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
|
N/A | |
Terminated |
NCT05116878 -
Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma
|
N/A | |
Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
Recruiting |
NCT03745560 -
Intraoperative EABR for Decision Making
|
||
Recruiting |
NCT04859335 -
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
|
N/A | |
Recruiting |
NCT04128345 -
Novel Multimodality Imaging for Navigation in Skull Base Surgery
|
||
Active, not recruiting |
NCT01199978 -
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT04057976 -
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
|
N/A | |
Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
Recruiting |
NCT05786144 -
Vestibular Schwannoma Organoids
|
||
Recruiting |
NCT03593577 -
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
|
||
Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|